Welcome to ESWI Airborne: Shaping the Future of Respiratory Virus Research. In this episode, we speak with two outstanding researchers whose work is shaping the future of influenza and respiratory virus science. This conversation forms part of our three-part series on life as a scientist.

Our guests are two recent ESWI Conference prize winners:

Dr Kevin Ciminski, recipient of the Claude Hannoun Prize for Best Body of Work.

He leads an independent research group at the Institute of Virology, University Medical Center Freiburg in Germany, where he studies virus–host interactions of emerging zoonotic influenza viruses.

Dr Marios Koutsakos, awarded the Young Scientist Vaccine Innovation Award.

He is a Group Leader at the Doherty Institute in Melbourne, Australia, focusing on influenza B viruses, immune imprinting, and developing broader and more durable influenza vaccine strategies.

Together, they explore what it means to build a scientific career, define a niche, establish a laboratory and contribute to an international research community. They reflect on the pivotal moments that drew them into virology, the balance between specialised research and big-picture questions, and the skills that have mattered most in their professional growth. They also share lessons learned from mentors and consider where early career scientists can make the greatest impact in the decade ahead.

Tune in to this extraordinary conversation exploring the important interplay between respiratory viruses and non-communicable diseases like diabetes, obesity, and cardiovascular disease. Why do people with chronic conditions face higher risks from infections? Could there be such a thing as "long-flu"? What are the long-term effects of viral infections? And why are viruses so tricky?

Join our three leading scientists as they unpack the bidirectional connection, clarify this unique opportunity to leverage awareness and the fundamental importance of joining forces across disciplines: Marco Goeijenbier(ESWI Board Member, intensivist at Spaarne Gasthuis and Senior Scientist at Erasmus MC), Tor Biering-Sørensen (cardiologist and Founding Head of the Center for Translational Cardiology in Copenhagen), and Kirsty Short (NHMRC research fellow, University of Queensland).

They will explain this pivotal moment to rethink disease prevention, reveal insights from the groundbreaking giga DANFLU trial, and show how the Interdisciplinary Disease Collaboration on Respiratory Infections and NCDs (IDC) is connecting the dots from lab bench to hospital bedside.

What are the causes for the steady and at times dramatic decline in vaccine confidence seen since the mid-90’s across certain age-groups and communities? Why has the public discourse changed? And how did the persistent and lingering myth linking vaccines to autism take hold?

In this insightful episode, a panel of accomplished experts tackle these pressing questions, offering astute explanations and powerful counter-strategies to combat misinformation and restore trust in vaccines.

Join Ted van Essen, TV doctor, GP and ESWI Board Member with many years of experience in public health work as chair of the Dutch Immunisation Foundation; Heidi Larson, Founder and Director of the Vaccine Confidence Project, author of “How vaccine rumours start”, and named one of the 100 most influential women in the world by the BBC in 2021; and, Sue Saville, former Medical Correspondent at Britain’s ITV News, now an independent health communications specialist bringing a wealth of experience as a speaker, writer, trainer and more.

In this episode, our distinguished experts and coalition partners unwrap and define key intervention strategies for acute respiratory viruses. Building on insights from previous episodes they offer fresh perspectives and bring to light the complexity of prevention, diagnostics and therapy.

Our discussion features ESWI Chair Colin Russell, Professor of Applied Evolutionary Biology, at the University of Amsterdam alongside contributions from Catherine Weil-Olivier, Honorary Professor of Paediatrics at Paris-Cité University, France, and Board Member of the Coalition for Life Course Immunisation and Barbara Rath, Pediatrician and Infectious disease Specialist and Co-founder and Chair at Vaccine Safety Initiative.

Why is seeking early testing so fundamental? How can translating discourse improve intervention efforts? What does understanding the patient journey entail? And finally, could an annual virus weather report become a reality? Do not miss this episode, where science meets strategy in the fight against respiratory viruses.

This episode was made possible from the kind support of Moderna, Viatris and AstraZeneca.

Learn about the fascinating story behind the intriguing Human metapneumovirus (hMPV) and how it was first discovered. Why were parents once asked about contact with birds? How can the recent outbreak in China make a difference? Join an insightful conversation with distinguished guests and leading experts Ab Osterhaus, Member of the ESWI board and Director of the Center of Infection Medicine and Zoonosis Research and Guest-Professor at the University of Veterinary Medicine Hannover, Germany, who first identified the virus together with Bernadette van den Hoogen, Associate Professor at Erasmus Medical Center in Rotterdam, and Ann Falsey, Professor of Medicine, Infectious Diseases, and co-director of the Vaccine Treatment and Evaluation Unit at the University of Rochester School of Medicine.

They tease out the subtle differences between HMPV, flu, and RSV, discuss the burden of disease, the role of diagnostics and the importance of fundamental research. Plus, why does public awareness matter and could a name change be on the horizon?

This episode was made possible from the kind support of AstraZeneca.

A riveting episode from three unique perspectives on intervention strategies and the ongoing challenges posed by Sars-Cov-2, the virus behind one of the deadliest pandemics in recent history. Featuring a fundamental researcher, a virologist, and a clinician, our speakers engage in a captivating talk on Covid-19. Is it endemic now? What’s new on the diagnostics and therapeutic front? How many annual vaccines can the public reasonably deal with?

Join us for this fascinating conversation that bridges research, clinical practice, and public health to address the evolving landscape of Covid-19 and other respiratory viruses.

This episode is supported by Moderna.

Tremendously exciting times and possibly underestimating the enormity of its impact. These are some of the comments we hear when experts share their insights on the recently available RSV vaccines. We are told about the disastrous first attempts of a vaccine 60 years ago and some of the road bumps leading to today’s success. In this episode, join us as we delve into the history, challenges, and triumphs of RSV vaccine development. Our renowned speakers give detailed accounts of the new RSV vaccines, including target population, critical gaps in vaccination for vulnerable groups, national immunisation programmes and the urgency of expanding access to resource poor settings.

RSV and the bumpy road towards a vaccine is supported by Moderna.

Flu Vaccines: Advancements, Challenges, and Global Impact – Expert Insights on Vaccine Platforms and Immune Responses

In this phenomenal episode, three leading experts in the field of vaccinology and immunology dive into the science behind various vaccine platforms and immune responses. Tune in as they explore the evolution of vaccines, from early, early vaccine platforms to cutting-edge technologies, and discuss the advantages and disadvantages of each approach. In a dynamic, educational conversation, we hear about the quest for the holy grail, the crucial role of CD8 T-cells, and the global challenges of vaccine accessibility and hesitancy.

Join Professor Ab Osterhaus, ESWI Executive Committee Member and Director of the Center of Infection Medicine and Zoonosis Research at the University of Veterinary Medicine Hannover, Germany; ESWI Board Member Florian Krammer, Professor of Vaccinology at the Department of Microbiology at the Icahn School of Medicine at Mount Sinai in New York, and Professor for Infection Biology at the Medical University of Vienna; and ESWI Associate Member Carolien van de Sandt, Senior Research Fellow, Department of Microbiology and Immunology at the Peter Doherty Institute, Australia in this thought-provoking discussion on the future of vaccines and global health.

With the support of Moderna and Viatris.